Bank of New York Mellon’s Ocera Therapeutics, Inc. OCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-31,880
| Closed | -$37K | – | 4446 |
|
|
2017
Q3 | $37K | Sell |
31,880
-5,143
| -14% | -$5.51K | ﹤0.01% | 4154 |
|
|
2017
Q2 | $43K | Buy |
37,023
+1,515
| +4% | +$1.76K | ﹤0.01% | 4152 |
|
|
2017
Q1 | $46K | Buy |
35,508
+3,628
| +11% | +$4.62K | ﹤0.01% | 4149 |
|
|
2016
Q4 | $67K | Sell |
31,880
-584
| -2% | -$1.36K | ﹤0.01% | 4089 |
|
|
2016
Q3 | $85K | Sell |
32,464
-1,672
| -5% | -$4.18K | ﹤0.01% | 4077 |
|
|
2016
Q2 | $65K | Sell |
34,136
-3,774
| -10% | -$9.92K | ﹤0.01% | 4133 |
|
|
2016
Q1 | $112K | Hold |
37,910
| – | – | ﹤0.01% | 3943 |
|
|
2015
Q4 | $119K | Buy |
37,910
+3,774
| +11% | +$12.9K | ﹤0.01% | 4017 |
|
|
2015
Q3 | $108K | Hold |
34,136
| – | – | ﹤0.01% | 4089 |
|
|
2015
Q2 | $129K | Sell |
34,136
-983
| -3% | -$3.77K | ﹤0.01% | 3992 |
|
|
2015
Q1 | $165K | Buy |
35,119
+9,823
| +39% | +$56.6K | ﹤0.01% | 3944 |
|
|
2014
Q4 | $161K | Buy |
25,296
+3,593
| +17% | +$21K | ﹤0.01% | 3944 |
|
|
2014
Q3 | $106K | Hold |
21,703
| – | – | ﹤0.01% | 4039 |
|
|
2014
Q2 | $166K | Hold |
21,703
| – | – | ﹤0.01% | 3882 |
|
|
2014
Q1 | $229K | Buy |
+21,703
| New | +$310K | ﹤0.01% | 3815 |
|
Bank of New York Mellon's OCRX Position: Q4 2017 in Review
Bank of New York Mellon sold out of Ocera Therapeutics, Inc. (OCRX) in Q4 2017, closing a stake of 31,880 shares — an estimated $37K sold.
Bank of New York Mellon first reported a position in OCRX in Q1 2014 and held it in 15 quarters. The position peaked at $229K in Q1 2014. 0 funds tracked by Wall St. Rank hold OCRX as of Q4 2017.
- Bank of New York Mellon reported no remaining Ocera Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
- Bank of New York Mellon sold 31,880 Ocera Therapeutics, Inc. shares in Q4 2017, an estimated $37K.
- Bank of New York Mellon first reported a position in Ocera Therapeutics, Inc. in Q1 2014 and held it in 15 quarters.
- Bank of New York Mellon's Ocera Therapeutics, Inc. position peaked at $229K in Q1 2014.
- 0 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q4 2017.
Based on Bank of New York Mellon's 13F filing for Q4 2017, filed 9 Feb 2018.